Skip to main content

Table 1 Characteristics of 1390 SCZ patients with T2D (n = 536) and without T2D (n = 854)

From: Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Characteristics

SCZ without T2D

n = 854 (61.44%)

SCZ with T2D

n = 536 (38.56%)

Corrected

p value****

Mean (SD)*

 Age (years)

45.83 (12.98)

57.07 (12.25)

< 0.0001

 SCZ duration (years)

18.57 (11.69)

26.30 (11.61)

< 0.0001

 BMI (kg/m2)

25.97 (4.54)

30.56 (6.75)

< 0.0001

n (%)**

 Male

516 (60.42%)

310 (57.84%)

0.467

 Female

338 (39.58%)

226 (42.16%)

 Number of subjects who reported outdoor physical activity in last week

16 (1.87%)

4 (0.75%)

0.172

 Number of subjects who reported no outdoor physical activity in last week

838 (98.13%)

532 (99.25%)

Median (IQR)***

 Number of Hospitalizations

4.00 (3.00–7.00)

3.00 (2.00–6.00)

< 0.0001

 Positive Symptoms

31.00 (27.00–36.00)

32.00 (27.00–37.00)

0.532

 Negative Symptoms

30.00 (26.50–34.00)

30.00 (25.00–34.00)

0.486

 General Psychopathology Scale

55.00 (48.00–64.00)

54.00 (47.00–64.00)

0.179

 PANSS total score

118.00 (105.00–130.50)

117.00 (103.00–131.00)

0.467

  1. SD: standard deviation; IQR: interquartile range
  2. *t-test, **x2 test, ***Wilcoxon Rank Sum test, ****Corrected p-value using Benjamini and Hochberg method for the comparison between SCZ patients with and without T2D